CIK 0001798749
- Emerging growth company
Jade Biosciences, Inc.
Sign in to watch- Ticker
- JBIO
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 831377888
- Phone
- +1 781-312-3013
- Business address
- 221 CRESCENT ST., BUILDING 23, SUITE 105, WALTHAM, MA, 02453
- Former names
- Aerovate Therapeutics, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 84 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-05-01 | NOYES TIMOTHY P CHIEF EXECUTIVE OFFICER | Option exercise · Stock Option (Right to Buy) 10b5-1 | −10,000 | 353,381 | ||
| 2024-04-17 | Dake Benjamin T SEE REMARKS | Option exercise 10b5-1 | +6,853 | $2.14 | $15K | 8,144 |
| 2024-04-17 | Dake Benjamin T SEE REMARKS | Sale 10b5-1 | −6,447 | $22.32 | $144K | 1,697 |
| 2024-04-17 | Dake Benjamin T SEE REMARKS | Sale 10b5-1 | −338 | $23.17 | $8K | 1,359 |
| 2024-04-17 | Dake Benjamin T SEE REMARKS | Sale 10b5-1 | −68 | $23.97 | $2K | 1,291 |
| 2024-04-17 | Dake Benjamin T SEE REMARKS | Option exercise · Stock Option (Right to Buy) 10b5-1 | −6,853 | 95,936 | ||
| 2024-04-17 | Gillies Hunter CHIEF MEDICAL OFFICER | Option exercise 10b5-1 | +4,000 | $1.74 | $7K | 7,251 |
| 2024-04-17 | Gillies Hunter CHIEF MEDICAL OFFICER | Sale 10b5-1 | −3,689 | $22.30 | $82K | 3,562 |
| 2024-04-17 | Gillies Hunter CHIEF MEDICAL OFFICER | Sale 10b5-1 | −311 | $23.33 | $7K | 3,251 |
| 2024-04-17 | Gillies Hunter CHIEF MEDICAL OFFICER | Option exercise · Stock Option (Right to Buy) 10b5-1 | −503 | 2,511 | ||
| 2024-04-17 | Gillies Hunter CHIEF MEDICAL OFFICER | Option exercise · Stock Option (Right to Buy) 10b5-1 | −3,497 | 539 | ||
| 2024-04-16 | NOYES TIMOTHY P CHIEF EXECUTIVE OFFICER | Option exercise 10b5-1 | +10,000 | $2.14 | $21K | 10,000 |
| 2024-04-16 | NOYES TIMOTHY P CHIEF EXECUTIVE OFFICER | Sale 10b5-1 | −4,491 | $24.40 | $110K | 5,509 |
| 2024-04-16 | NOYES TIMOTHY P CHIEF EXECUTIVE OFFICER | Sale 10b5-1 | −5,509 | $24.94 | $137K | 0 |
| 2024-04-16 | NOYES TIMOTHY P CHIEF EXECUTIVE OFFICER | Option exercise · Stock Option (Right to Buy) 10b5-1 | −10,000 | 363,381 | ||
| 2024-04-10 | Eldridge George A SEE REMARKS | Option exercise 10b5-1 | +7,500 | $2.14 | $16K | 9,460 |
| 2024-04-10 | Eldridge George A SEE REMARKS | Sale 10b5-1 | −6,729 | $26.77 | $180K | 2,731 |
| 2024-04-10 | Eldridge George A SEE REMARKS | Sale 10b5-1 | −771 | $27.56 | $21K | 1,960 |
| 2024-04-10 | Eldridge George A SEE REMARKS | Option exercise · Stock Option (Right to Buy) 10b5-1 | −7,500 | 43,763 | ||
| 2024-04-09 | GRAYZEL DAVID S. Director | Sale | −11,882 | $28.15 | $334K | 14,502 |
Page 4 of 16 · 315 trades